KROS - Keros Therapeutics inks licensing deal for KER-050 in China

Keros Therapeutics (NASDAQ:KROS) has entered into a licensing agreement with Hansoh (Shanghai) Healthtech Company, a subsidiary of Hansoh Pharmaceutical Group in China. Under the terms of the agreement, Hansoh will obtain an exclusive license from Keros to develop, manufacture and commercialize KER-050 within the territories of mainland China, Hong Kong, and Macau. Keros will receive a $20M upfront payment and will also be eligible to receive up to $170.5M in milestones, plus tiered royalties on net product sales ranging from the low double digit to high teens. Hansoh is responsible for the development, regulatory approval and commercialization of KER-050 in mainland China, Hong Kong, and Macau.

For further details see:

Keros Therapeutics inks licensing deal for KER-050 in China